Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 8/20 | 0.72 |
| ▸ | RORC | P51449 | 5/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29359283 | 0.92 | KCNN4 (0.72) | KCNN4RORCARDRD2AAK1 | |
| SCHEMBL22470161 | 0.91 | KCNN4 (0.59) | KCNN4RORCARDRD2TAS1R3 | |
| SCHEMBL29356770 | 0.89 | KCNN4 (0.76) | KCNN4RORCARTAS1R3TAS1R1 | |
| SCHEMBL29354486 | 0.88 | KCNN4 (0.55) | KCNN4RORCARTAS1R3TAS1R1 | |
| SCHEMBL29699684 | 0.88 | KCNN4 (0.74) | KCNN4DRD2AAK1 | |
| SCHEMBL29353670 | 0.87 | KCNN4 (0.79) | KCNN4ARTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29699543 | 0.85 | KCNN4 (0.66) | KCNN4RORCDRD2LMNAPOLB | |
| SCHEMBL29353715 | 0.84 | KCNN4 (1.00) | KCNN4ARTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29358422 | 0.84 | KCNN4 (0.65) | KCNN4RORC | |
| SCHEMBL29356985 | 0.84 | KCNN4 (0.66) | KCNN4RORCAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2026-02-19 | — | — | US | disclosed |
| US-12391644-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| EP-3941903-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2025-07-16 | — | — | EP | disclosed |
| US-20240368077-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA AS (DK) | 2024-11-07 | — | — | US | disclosed |
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | disclosed |
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391644-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885RORC 2789/4885AR 3894/4885 |
| US-20240368077-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885RORC 2964/4885AR 4214/4885 |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | KCNN4 57/4885RORC 2964/4885AR 4214/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | KCNN4 48/4885RORC 2789/4885AR 3894/4885 |
| US-20260049054-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SCN10A, KCNK10, KCNJ2 | KCNN4 43/4885RORC 4489/4885AR 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.